Inhibits Class I and II histone deacetylases (HDACs); induces accumulation of acetylated histones H2A, H2B, H3 and H4 in transformed cultured cells. Suppresses cell growth in a range of cancer cell lines; induces apoptosis in cutaneous T cell lymphoma cells in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler et al.
Cancer Res., 2000;60:5165
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
Leoni et al.
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
Marks and Breslow
Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds.
Huangfu et al.